New food enzyme exposure tool paves the way for evaluations
EFSA scientists have devised a way to more accurately estimate consumer exposure to enzymes used in food production, improving their safety evaluation as required by EU law.
Use of the new approach in four scientific opinions published yesterday paves the way for the evaluation of the remaining 300 applications.
Dr Christina Tlustos, an exposure expert who sits on EFSA’s Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF), which developed the approach, said: “We have developed an exposure tool which can be tailored to each food process involving food enzymes. The tool uses technical conversion factors, which means we can combine food consumption data with enzyme use levels and take into account the level of transfer of food enzymes into food products.”
Input from stakeholders
Prof Karl-Heinz Engel, the chair of the food enzymes working group and a CEF Panel member, said: “The experts on the working group decided which technical input data to use. During the development of the tool stakeholders provided some useful insights and additional data.
“By harmonising both food enzyme use levels and food consumption data we can estimate consumer exposure to these substances much more accurately than before.”
The same methodology will be applied to all remaining food enzymes applications scheduled for assessment by EFSA.
What are food enzymes?
Enzymes are protein molecules that catalyse chemical reactions. They have been used in the production of foods such as bread and beer for centuries.
Historically enzymes are considered to be non-toxic and not a safety concern for consumers since they are produced naturally by living organisms and present in ingredients used to make food. However, today’s foods are also made using food enzymes produced industrially. These enzymes are extracted from plant and animal tissues or produced by fermentation of microorganisms.
Industrially produced food enzymes are subject to a scientific assessment under Regulation EC 1332/2008 to ensure they are safe for use in food production. EFSA has received over 300 applications for food enzyme safety evaluations from the European Commission.
In September 2016, the CEF Panel published a new methodology for dietary exposure to food enzymes based on actual consumption data collected from individual European citizens.
- Scientific opinion on Safety evaluation of the food enzyme β‑amylase obtained from barley (Hordeum vulgare)
- Scientific opinion on Safety evaluation of the food enzyme β-amylase obtained from wheat (Triticum spp.)
- Scientific opinion on Safety evaluation of the food enzyme β-amylase obtained from soybean (Glycine max) whey
- Scientific opinion on Safety evaluation of the food enzyme endo-1,4-β-xylanase obtained from genetically modified Aspergillus niger strain XYL
Tel. +39 0521 036 149
Latest News from
State aid: EC approves alternative to divestment commitment for Royal Bank of Scotland19/09/2017 14:10:00
The EC has approved under EU State aid rules the alternative package proposed by the UK authorities to replace the commitment for Royal Bank of Scotland (RBS) to divest Williams & Glyn. The alternative package will increase competition in the UK SME banking market.
EC welcomes stakeholders' views on the future of EU finances19/09/2017 12:49:00
As part of the process started with the publication of the Reflection Paper on the Future of EU finances, the EC is organising on 25 September 2017 a conference on the challenges ahead of the EU budget and the ways to address them.
Juncker: ‘I don't intend to force countries to join the euro if they are not willing or not able to do so'18/09/2017 15:20:00
Jean-Claude Juncker, the President of the EC,has defended his proposal to expand the eurozone. All EU Member States should have the possibility to introduce the euro, but no one would be forced to do so, Juncker said on Thursday.
EMA concludes review of human factor VIII medicines authorised in EU.18/09/2017 13:20:00
The European Medicines Agency (EMA) has concluded that there is no clear & consistent evidence of a difference in the incidence of inhibitor development between the two classes of factor VIII medicines: those derived from plasma and those made by recombinant DNA technology.
ESMA lays out procedure for ETDs access to CCPs under MiFID II18/09/2017 12:42:00
The European Securities and Markets Authority (ESMA) has issued a procedure under Markets in Financial Instruments Regulation (MiFIR) laying out the steps for trading venues to temporarily opt-out from access provisions for exchange-traded derivatives (ETDs).